CO6541649A2 - 3.6 -diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotínicos neuronales de aceticolina - Google Patents

3.6 -diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotínicos neuronales de aceticolina

Info

Publication number
CO6541649A2
CO6541649A2 CO12111727A CO12111727A CO6541649A2 CO 6541649 A2 CO6541649 A2 CO 6541649A2 CO 12111727 A CO12111727 A CO 12111727A CO 12111727 A CO12111727 A CO 12111727A CO 6541649 A2 CO6541649 A2 CO 6541649A2
Authority
CO
Colombia
Prior art keywords
compounds
receptors
aceticoline
legands
heptans
Prior art date
Application number
CO12111727A
Other languages
English (en)
Inventor
Srinivisa Rao Akireddy
Balwinder Singh Bhatti
Yunde Xiao
Jon Paul Strachan
Srinivasa Murthy
Ronald Joseph Heemstra
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6541649(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CO6541649A2 publication Critical patent/CO6541649A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona concompuestos que se unen y modulan la actividad dereceptores nicotinicos neuronales de acetilcolina, conprocesos para preparar estos compuestos, concomposiciones farmacéuticas que contienen estoscompuestos, y con métodos para usar estos compuestospara tratar una amplia variedad de condiciones ytrastornos, que incluyen aquellos asociados a la disfuncióndel sistema nervioso central (SNC).
CO12111727A 2009-12-07 2012-07-04 3.6 -diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotínicos neuronales de aceticolina CO6541649A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26721809P 2009-12-07 2009-12-07

Publications (1)

Publication Number Publication Date
CO6541649A2 true CO6541649A2 (es) 2012-10-16

Family

ID=43608875

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12111727A CO6541649A2 (es) 2009-12-07 2012-07-04 3.6 -diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotínicos neuronales de aceticolina

Country Status (20)

Country Link
US (2) US8802694B2 (es)
EP (1) EP2509982A1 (es)
JP (1) JP2013512922A (es)
KR (1) KR20120120190A (es)
CN (1) CN102648202A (es)
AR (1) AR079271A1 (es)
AU (1) AU2010328419A1 (es)
BR (1) BR112012013765A2 (es)
CA (1) CA2782409A1 (es)
CL (1) CL2012001483A1 (es)
CO (1) CO6541649A2 (es)
EC (1) ECSP12012023A (es)
IL (1) IL219960A0 (es)
MX (1) MX2012006484A (es)
PE (1) PE20121556A1 (es)
RU (1) RU2012128583A (es)
SG (1) SG181109A1 (es)
TW (1) TW201138776A (es)
WO (1) WO2011071758A1 (es)
ZA (1) ZA201204143B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
CN102648202A (zh) * 2009-12-07 2012-08-22 塔加西普特公司 作为神经元烟碱乙酰胆碱受体配体的3,6-二氮杂双环[3.1.1]庚烷
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
CN102875556B (zh) * 2011-07-12 2016-03-30 天津药明康德新药开发有限公司 (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
JP2016513681A (ja) 2013-03-14 2016-05-16 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
DE69842058D1 (de) 1997-10-27 2011-01-27 Neurosearch As Heteroaryl Diazacycloalkane als cholinergische Ligande für Nikotin-Acetylcholin-Rezeptoren
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
WO2000066586A1 (en) * 1999-05-04 2000-11-09 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
JP2003529547A (ja) 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
JP2003513054A (ja) 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2003008559A2 (en) 2001-07-19 2003-01-30 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
CA2480488A1 (en) * 2002-05-07 2003-11-20 Neurosearch A/S Novel diazabicyclic biaryl derivatives
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
RS20060391A (en) * 2003-12-22 2008-11-28 Memory Pharmaceuticals Corporation, Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
ITMI20040954A1 (it) * 2004-05-12 2004-08-12 Univ Degli Studi Milano Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CA2716863A1 (en) * 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
CN102648202A (zh) * 2009-12-07 2012-08-22 塔加西普特公司 作为神经元烟碱乙酰胆碱受体配体的3,6-二氮杂双环[3.1.1]庚烷

Also Published As

Publication number Publication date
IL219960A0 (en) 2012-07-31
KR20120120190A (ko) 2012-11-01
SG181109A1 (en) 2012-07-30
ECSP12012023A (es) 2012-08-31
WO2011071758A1 (en) 2011-06-16
PE20121556A1 (es) 2012-12-05
US20120309737A1 (en) 2012-12-06
BR112012013765A2 (pt) 2016-04-26
US20140315880A1 (en) 2014-10-23
ZA201204143B (en) 2013-02-27
US8802694B2 (en) 2014-08-12
RU2012128583A (ru) 2014-01-20
CA2782409A1 (en) 2011-06-16
TW201138776A (en) 2011-11-16
EP2509982A1 (en) 2012-10-17
AR079271A1 (es) 2012-01-04
CL2012001483A1 (es) 2013-01-18
AU2010328419A1 (en) 2012-06-21
MX2012006484A (es) 2012-08-01
CN102648202A (zh) 2012-08-22
JP2013512922A (ja) 2013-04-18

Similar Documents

Publication Publication Date Title
CO6541649A2 (es) 3.6 -diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotínicos neuronales de aceticolina
UY32449A (es) Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal
CO6501143A2 (es) Preparación y aplicaciones terapéuticas de (2s,3r)-n-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-difluorobenzamida
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
MY159856A (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
CL2014001212A1 (es) Compuestos heterobiciclicos condensados, inhibidores de fosfodiesterasa tipo 10a; composicion farmaceutica que los comprende; y metodo para tratar un trastorno seleccionado entre trastornos neurologicos y trastornos psiquiatricos.
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201491534A1 (ru) Ингибиторы бета-секретазы
MX2010005648A (es) Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
MX2010009727A (es) Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
NI201000168A (es) Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa.
TN2015000032A1 (en) Inhibitors of beta-secretase
AR060088A1 (es) Metodos para tratar trastornos cognitivos y otros afines
ECSP11011135A (es) Síntesis de novedosas formas de sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi) piridina
UY34281A (es) "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina
WO2014052398A8 (en) Inhibitors of beta-secretase
CL2008000668A1 (es) Compuestos derivados de 3-ciano-4-(4-fenil-piperidin-1-il)piridin-2-ona; proceso de preparacion; composicion farmaceutica que los comprende; y su uso para tratar trastornos del sistema nervioso central.